OKYO
OKYO Pharma LimitedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-17.20
P/S
0.00
EV/EBITDA
-5.86
DCF Value
$-0.11
FCF Yield
-5.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
102.9%
ROA
-99.3%
ROIC
154.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-2.6M | $-0.07 |
| Q4 2025 | $0.00 | $-2.0M | $-0.04 |
| FY 2025 | $0.00 | $-4.7M | $-0.12 |
| Q2 2025 | $0.00 | $-2.7M | $-0.08 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
GB
Exchange
NASDAQ
Beta
-0.12
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.